1. Scrip
  2. >>Business

AbbVie Needs To Freshen Up

 
• By Elizabeth Cairns and Edwin Elmhirst

With half of its 2023 sales coming from aging blockbusters like Humira and Botox, AbbVie needs new blood.    

Economic recovery and growing wealth business metaphor as a group of trees shaped as a dollar sign growing leaves and bearing fruit as a symbol of wealth and financial success in a growth industry.

Big pharma companies must constantly reinvent themselves if they are to ensure their revenues grow, developing new therapies to replace the older drugs whose patents are approaching expiry. AbbVie Inc. in particular needs to accelerate this process: nearly half of its revenues last year came from products that are more than 15 years old.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip

Another CRL Prompts Questions About Regeneron’s Regulatory Operations

 
• By Alaric DeArment

CEO Len Schleifer explained on the company’s Q1 earnings call that most of the complete response letters the company has received related to third-party suppliers, not efficacy or safety.

Novartis Doubles Down On Push For Higher Drug Prices In Europe

 
• By Jessica Merrill

CEO Vas Narasimhan urged European governments to spend more to support drug innovation during Novartis's first-quarter results call.

Soriot Cautions Europe Amid More US Expansion

 
• By Kevin Grogan

The AstraZeneca CEO again calls for rich European countries to pay more for new drugs because "a model where the US funds innovation in our industry for the entire world doesn't work."